Parkman Healthcare Partners LLC Invests $1.43 Million in Upstream Bio, Inc. $UPB

Key Points

• Parkman Healthcare Partners LLC has invested approximately $1.43 million in Upstream Bio, acquiring 233,563 shares, which represents about 0.43% ownership of the company as of the recent quarter.
• Upstream Bio reported a loss of $0.74 earnings per share for the latest quarter, missing estimates, but generated revenue of $0.94 million, exceeding expectations.
• Despite recent struggles, Upstream Bio has a consensus rating of "Buy" from analysts, with an average target price of $56.50.

Parkman Healthcare Partners LLC purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 233,563 shares of the company's stock, valued at approximately $1,429,000. Parkman Healthcare Partners LLC owned approximately 0.43% of Upstream Bio at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of UPB. BNP Paribas Financial Markets purchased a new stake in shares of Upstream Bio during the 4th quarter valued at approximately $25,000. New York State Common Retirement Fund acquired a new stake in Upstream Bio during the 1st quarter worth approximately $29,000. Tower Research Capital LLC TRC purchased a new position in Upstream Bio in the 4th quarter valued at approximately $47,000. XTX Topco Ltd acquired a new position in shares of Upstream Bio in the first quarter worth $78,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Upstream Bio during the first quarter worth $92,000.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Upstream Bio from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $56.50.

Upstream Bio Price Performance

NASDAQ:UPB traded up $0.12 during midday trading on Thursday, hitting $17.92. 305,341 shares of the company were exchanged, compared to its average volume of 373,425. Upstream Bio, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $29.46. The company has a fifty day simple moving average of $15.24 and a 200 day simple moving average of $11.09.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.32 million. Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%. As a group, sell-side analysts predict that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.